Use of COTA Nodal Address Highlights Variance in Cancer Care Cost: An Interview With Donald M. Berwick, MD, MPP
Donald M. Berwick, MD, MPP, the former CMS administrator who is president emeritus and senior fellow at the Institute for Healthcare Improvement, discusses cost variation in cancer care found through the digital classification system the COTA Nodal Address.
Radiation Oncology’s Role in the Next Chapter of Payment Reform
An ideal alternative payment model would reward radiation oncologists for participation in a value-based payment arrangement that grants them the freedom to make care delivery decisions based on patient needs and in accordance with clinical guidelines, says ASTRO's Anne Hubbard, MBA.
ACCC and ASCO Collaborative Targets Disparities in Cancer Clinical Trials
ACCC president Randall Oyer, MD, gives insight into the ongoing collaboration between the ACCC and ASCO to foster minority participation in cancer clinical trials.
Flying the Plane While You Build It
In this issue of Evidence-Based Oncology™ we see a foreshadowing of what the future of cancer care innovation could look like and how we may learn to move forward, safely, at an ever-accelerating pace.
The Untapped Potential of Cell and Gene Therapy
Excitement around gene therapy is back and greater than before. Although safety remains a concern, investigators are breaking ground in cell and gene therapy, and many believe that ultimately, a string of cancer cures will follow.
Interview: Tanya Siddiqi, MD, Discusses the Promise of Reduced Toxicity With Liso-Cel
Tanya Siddiqi, MD, director of the chronic lymphocytic leukemia program at Toni Stephenson Lymphoma Center provides insights on what the arrival of liso-cel could mean in the treatment landscape.
FDA Approves Osimertinib for Adjuvant Treatment of Early-Stage EGFR-Mutated NSCLC
The new indication for osimertinib (Tagrisso) marks the first FDA approval of an adjuvant treatment for non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R mutations.
Certain NSCLC Patients Are More Likely to Respond to Immunotherapy, Study Results Show
A recent study investigated what makes some non-small cell lung cancer patients with a type of human leukocyte antigen (HLA) called B44 are more likely than others to respond to immunotherapy.
Possible Treatment Identified for Aggressive NSCLC Subset
Researchers from the Children’s Medical Center Research Institute at the University of Texas Southwestern discovered a potential treatment for patients with non–small cell lung cancer (NSCLC) who have KRAS and LKB1 mutations.
Contributor: A Practical Path Forward to More Patient-Centered Value Assessment
To ensure that value assessment accounts for patient needs, we need a better understanding of the outcomes that are most important to patients, write authors from COVIA Health Solutions and the University of Washington School of Pharmacy.
Proximity to Treatment, Racial Disparities Are Seen in Ovarian Cancer Survival
Patients with ovarian cancer who lived within 10 miles of Kansas’s only National Cancer Institute–designated cancer center, and those of a non-White race, were shown to have less of a survival advantage.
Lung Cancer Screenings Fall, Biopsy Rates Rise During COVID-19
Deferred low-dose computed tomography lung cancer screening during the coronavirus disease 2019 (COVID-19) pandemic has worsened outcomes for patients with lung cancer, a new study found.
As Mammography Screenings Drop, Advanced Breast Cancer Cases Increase in First Months of COVID-19
The study, presented at the 2020 San Antonio Breast Cancer Symposium, also found that time to first treatment dropped during this period of the coronavirus disease 2019 (COVID-19) pandemic.
Azacitidine Is Shown to Improve Overall, Relapse-Free Survival in Older Adults With AML
Older adults with acute myeloid leukemia (AML) saw increased overall and relapse-free survival, as well as preserved quality of life, following oral administration of 300-mg azacitidine.
FDA Updates Ibrutinib Label With 5-Year Data in Waldenström Macroglobulinemia
The newly approved expanded label includes data from the final analysis of the phase 3 iNNOVATE study of ibrutinib plus rituximab vs rituximab alone.
FDA Grants Tiragolumab Breakthrough Therapy Designation for PD-L1–High NSCLC
Genentech's tiragolumab, a novel immunotherapy for non-small cell lung cancer with PD-L1 expression, is the first anti-TIGIT therapy to be granted Breakthrough Therapy Designation.
Experts Discuss PARP Inhibition in Prostate and Ovarian Cancers
Experts in gynecologic oncology and genitourinary oncology discuss the current state of PARP inhibitors in prostate and ovarian cancers.
Cost of Home vs Clinic Administration of Paclitaxel in Metastatic Breast Cancer
Home administration of oral paclitaxel and encequidar is associated with potential cost savings for payers compared with clinic administration of intravenous chemotherapy in metastatic breast cancer patients.
Supplemental Material: Cost of Home vs Clinic Administration of Paclitaxel in Metastatic Breast Cancer
2 Commerce Drive Cranbury, NJ 08512